In this webinar delivered in collaboration with La Roche-Posay, Dermatologist Dr Kate DeAmbrosis provides exclusive insights into harnessing the power of the microbiome in the treatment of acne and atopic dermatitis.
The cutaneous microbiome holds therapeutic promise for inflammatory skin diseases like atopic dermatitis and acne.
Recent research highlights the microbiota’s significance in healthy skin and disease development and is an emerging potential field for therapeutic targets. Current treatments rely on antimicrobials to manage inflammation, yet they pose risks such as antimicrobial resistance and adverse effects.
Harnessing the skin’s natural microbial communities through targeted biotherapy has the potential to revolutionise treatment approaches.
In the full webinar recording below, explore the current evidence supporting the microbiome’s role in these inflammatory skin diseases and learn how microbiome-directed therapeutics may be a promising avenue for managing them.
Dr Kate DeAmbrosis completed her medical degree at the University of Newcastle and undertook basic surgical training at the Princess Alexandra Hospital before embarking on specialist training through the Australasian College of Dermatology. Her training in Dermatology was completed at Princess Alexandra Hospital, Mater Adults and Children’s Hospitals, Royal North Shore Hospital, and Royal Brisbane and Women’s Hospitals. Dr DeAmbrosis received the Ken Paver Medal for Clinical Sciences and the Merck Sharpe and Dohme award for research. Her special interests are in skin cancer detection and treatment, acne, psoriasis, and eczema as well as paediatric and vulval dermatology.
Watch another webinar: Golden Rules of Skin Cancer Management
Engaging with this blog can help meet your annual
|
How to claim your CPD hours
|